Article
Oncology
Shozo Ohsumi, Sachiko Kiyoto, Mina Takahashi, Fumikata Hara, Seiki Takashima, Kenjiro Aogi, Miwa Matsuda, Naomi Yamamura, Miyuki Doi
Summary: The study aimed to assess the effects of scalp cooling on hair loss in Japanese women undergoing breast cancer chemotherapy. The results showed that the efficacy of scalp cooling for mitigating alopecia in Asian women is similar to that in Caucasian women.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Oncology
Shozo Ohsumi, Sachiko Kiyoto, Mina Takahashi, Seiki Takashima, Kenjiro Aogi, Sachie Shimizu, Miyuki Doi
Summary: The study evaluated hair recovery after chemotherapy with scalp cooling for 117 Japanese female breast cancer patients, showing that patients who completed scalp cooling during chemotherapy had significantly better hair recovery outcomes compared to those who discontinued it, with a longer duration of effect.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Oncology
Robin E. Heibloem, Manon M. C. Komen, Onaedo U. C. Ilozumba, Corina J. G. van den Hurk
Summary: This observational study investigated the effects of wetting hair before scalp cooling on preventing chemotherapy-induced alopecia and on tolerance in cancer patients. The results suggested that wetting hair improves the use of head covers and tolerance during scalp cooling for patients receiving docetaxel, carboplatin-paclitaxel, or 5-fluorouracil-epirubicin-cyclophosphamide-docetaxel. However, the effects were not significant for patients receiving 5-fluorouracil-epirubicin-cyclophosphamide.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Oncology
Luisa Carbognin, Cristina Accetta, Danilo Di Giorgio, Paola Fuso, Margherita Muratore, Giordana Tiberi, Francesco Pavese, Tatiana D'Angelo, Alessandra Fabi, Diana Giannarelli, Alba Di Leone, Stefano Magno, Giorgia Garganese, Alejandro Martin Sanchez, Daniela Andreina Terribile, Gianluca Franceschini, Riccardo Masetti, Giovanni Scambia, Ida Paris
Summary: This study evaluated the efficacy and safety of a scalp cooling device in preventing chemotherapy-induced alopecia in breast cancer patients. The results demonstrated that the scalp cooling device was effective in preventing hair loss and had a low rate of adverse events.
Article
Oncology
Asma Dilawari, Christopher Gallagher, Princess Alintah, Ami Chitalia, Shruti Tiwari, Richard Paxman, Lucile Adams-Campbell, Chiranjeev Dash
Summary: Despite FDA approval, scalp cooling devices may have limited efficacy in preventing alopecia in Black women, potentially due to differences in hair thickness, hair volume, and limitations of cooling cap design.
Article
Oncology
Cynthia Villarreal-Garza, Fernanda Mesa-Chavez, Ma Ria Alejandra Garza-Ledezma, Omar Pena-Curiel, Bertha Alejandra Martinez-Cannon, Mauricio Canavati-Marcos, Servando Cardona-Huerta
Summary: This study evaluated the effectiveness of scalp cooling (SC) among breast cancer patients receiving different chemotherapy regimens. Results showed that SC was highly effective in preventing alopecia, particularly with taxane-based regimens. The sequence of chemotherapy administration may have a significant impact on the success of SC for preventing hair loss.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Lucy Rose, Patrick M. M. Schnell, Lindsey Radcliff, Maryam Lustberg, Brittany Dulmage
Summary: For patients with cancer, alopecia caused by chemotherapy has negative effects on personal identity, body image, self-esteem, quality of life, and medical decision-making. Scalp cooling is a technique that can prevent this side effect by causing localized vasoconstriction of blood vessels. A study investigated factors influencing patients' decisions to use scalp cooling, and found that patient age, race, insurance status, and chemotherapy regimen played important roles.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Nursing
Steffi Renehan, Monika Tencic, Kylie Jackson, Meinir Krishnasamy
Summary: This study aimed to understand women's experiences and expectations of scalp cooling during chemotherapy for early-stage breast cancer. Many women reported losing more hair than they expected and feeling inadequately prepared for the discomfort of scalp cooling. The study highlighted the importance of providing comprehensive preparatory information and ensuring nurses are well informed about scalp cooling processes.
JOURNAL OF CLINICAL NURSING
(2022)
Review
Oncology
Shurui Wang, Ting Yang, Aomei Shen, Wanmin Qiang, Zihan Zhao, Fangyuan Zhang
Summary: Scalp cooling devices can significantly improve chemotherapy-induced alopecia in breast cancer patients, but the side effects of scalp cooling therapy, such as headache, dizziness, and neck pain, cannot be ignored.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Oncology
Xin-Yu Zhang, Ke-Lu Yang, Wen-Qing Liu, Jie Huang, Ning Ning
Summary: This overview summarizes the effectiveness, safety, and tolerance of scalp cooling for preventing chemotherapy-induced alopecia. The results indicate that scalp cooling is effective in preventing hair loss and does not increase the risk of scalp metastases.
ONCOLOGY NURSING FORUM
(2022)
Article
Dermatology
Sean Singer, Elizabeth Tkachenko, Priyank Sharma, Caroline Nelson, Arash Mostaghimi, Nicole R. LeBoeuf
Summary: Chemotherapy-induced alopecia is a psychological challenge for patients, and scalp cooling can prevent or reduce hair loss. In the United States, only 43.9% of Medicare-billed chemotherapy infusions occur in zip codes less than 12.5 miles from a scalp cooling center.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2021)
Review
Pharmacology & Pharmacy
X-F Shen, L-X Ru, X-B Yao
Summary: The study found that patients undergoing chemotherapy with scalp cooling therapy had a 41% lower risk of alopecia compared to those without scalp cooling. However, around 66% of subjects reported discomfort with the use of the scalp cooling system. While scalp cooling is effective in reducing hair loss, there may be limitations due to reported complaints of discomfort.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2021)
Editorial Material
Oncology
Versha A. Pleasant, Ava S. Purkiss, Sofia D. Merjaver
Summary: Chemotherapy-induced alopecia (CIA) is a devastating side effect of breast cancer treatment that affects all racial groups, but holds unique historical, social, political, and cultural significance for Black patients. Oncologists should strive to understand the impact of CIA on their Black patients.
Article
Oncology
Leni van Doorn, Mandy M. van Rosmalen, Wendy M. van der Deure, Esther Oomen-de Hoop, Robert Porrazzo, Sophie M. Wijngaard, Ingrid A. Boere, Paola Veenstra, Eman Ibrahim, Peter de Bruijn, Lena E. Friberg, Stijn L. W. Koolen, Ron H. J. Mathijssen, Agnes Jager
Summary: This study found that scalp cooling did not have a significant impact on the pharmacokinetics of paclitaxel in female cancer patients with solid tumors, indicating that it does not affect the efficacy or toxicity of the drug, nor does it alter the incidence of hair loss.
Article
Oncology
Rieneke T. Lugtenberg, Corina J. G. van den Hurk, Carolien H. Smorenburg, Linda Mosch, Danny Houtsma, Margaret A. G. den Hollander-van Deursen, Ad A. Kaptein, Hans Gelderblom, Judith R. Kroep
Summary: This study found that a post-infusion cooling time (PICT) of 20 minutes is as effective as 45 and 90 minutes in preventing paclitaxel-induced alopecia in patients receiving weekly paclitaxel treatment. The results suggest that shortening the PICT can be a new standard of care.
SUPPORTIVE CARE IN CANCER
(2022)